ORG
Pfizer’s Revolutionary Hemophilia B Gene Therapy Gains FDA Approval and Introduces Unique Warranty Program
Pfizer, FDA, Hemophilia B, Gene Therapy, Approval, Warranty, Treatment, Genetic Disorder, Blood Clotting, Healthcare, Biotechnology
AbbVie’s Skyrizi and Rinvoq Drive Growth, Counteracting Humira Decline
AbbVie, Skyrizi, Rinvoq, Humira, full-year outlook, pharmaceutical industry, revenue growth, drug sales, immunology drugs
Cigna’s Evernorth Pushes for Increased Humira Biosimilar Adoption
Cigna, Evernorth, Humira, biosimilars, healthcare, pharmacy services, cost savings, patient access, AbbVie
Novo Nordisk Faces Scrutiny Over High Prices of Ozempic and Wegovy
Novo Nordisk, Ozempic, Wegovy, drug prices, Senator Bernie Sanders, diabetes, obesity
UCB’s Strategic Shift: Bristol Myers ADC Partner’s CEO Takes the Helm
UCB, management changes, CEO, Bristol Myers, ADC partner, strategic shift, pharmaceutical industry.
Gilead’s Strategic Focus: CymaBay Liver Drug, Trodelvy Data, and Long-Acting PrEP in 2023
Gilead, CymaBay, liver drug, Trodelvy, readouts, long-acting PrEP, 2023, strategic focus.
FDA Approves Pfizer’s Hemophilia B Gene Therapy with a $3.5 Million Price Tag
Pfizer, FDA, hemophilia B, gene therapy, approval, pricing, healthcare, biotechnology, rare diseases, genetic disorders, treatment cost.
GSK Files Lawsuit Against Pfizer and BioNTech for Alleged COVID-19 Vaccine Patent Violation
GSK, Pfizer, BioNTech, COVID-19, patent infringement, vaccine, lawsuit, intellectual property
Merck & Co.’s Q1 Success Driven by Keytruda, Ups 2024 Outlook
Merck & Co., Q1 earnings, Keytruda, pharmaceuticals, cancer treatment, 2024 forecast
Regeneron Pharmaceuticals Expands Gene Editing Capabilities with Mammoth Biosciences Partnership
Regeneron, Mammoth Biosciences, gene editing, CRISPR, partnership, biotechnology, healthcare, pharmaceuticals, genetic research, therapeutic development.